Nordisk is convinced that it will be able to launch the pill version of its product this decade. experimental weight loss drug amicretinThe company’s development chief told Reuters on Friday, a day after it announced solid data from early trials.
“I never commit to deadlines, but I would feel very comfortable if I said that, at least, in this decade”declared Martin Holst Lange in an interview.
Novo shares rose more than 8% to hit all-time highs on Thursday, when the company told investors that a Phase I trial of the pill version of amicretin showed participants lost 13.1% of their weight after 12 weeks, an early reduction greater than that of Wegovy.
Shares of the pharmaceutical company, which surpassed Tesla Inc. in market value on Thursday, were down 0.9% on the day, but are still on track for a weekly rise of 7.1%.
Investors said the news shows that the Danish company, originally known as an insulin maker, has more in the pipeline than its successful Wegovy. Its shares have more than tripled since June 2021, when it launched Wegovy in the United States.
He hopes his new experimental anti-obesity drugs, cagrisema and amicretin, will be more effective than Wegovy for weight loss.
According to Lange, after 12 weeks of treatment with amicretin, more than 80% of participants were still taking the drug, which is an “impressive” retention rate that suggests that the doses are safe and that patients tolerate it well, without side effects. important secondary
He also added that “it would also be a likely hypothesis” that the new drugs would have cardiac benefits similar to those of Wegovy.
By Maggie Fick and Jacob Gronholt-Pedersen, Reuters
Source: Ambito
I am an author and journalist who has worked in the entertainment industry for over a decade. I currently work as a news editor at a major news website, and my focus is on covering the latest trends in entertainment. I also write occasional pieces for other outlets, and have authored two books about the entertainment industry.
